JPY 610.0
(-0.65%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 295.46 Million JPY | 73.7% |
2022 | 170.1 Million JPY | 14.64% |
2021 | 148.37 Million JPY | 324.99% |
2020 | 34.91 Million JPY | -25.18% |
2019 | 46.66 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 299.98 Million JPY | 1.53% |
2023 Q2 | 205.84 Million JPY | 22.78% |
2023 Q4 | 295.46 Million JPY | 22.55% |
2023 Q3 | 241.1 Million JPY | 17.13% |
2023 FY | 295.46 Million JPY | 73.7% |
2023 Q1 | 167.65 Million JPY | -1.44% |
2022 Q3 | 87 Million JPY | -3.16% |
2022 FY | 170.1 Million JPY | 14.64% |
2022 Q4 | 170.1 Million JPY | 95.52% |
2022 Q2 | 89.83 Million JPY | 0.0% |
2021 FY | 148.37 Million JPY | 324.99% |
2020 FY | 34.91 Million JPY | -25.18% |
2019 FY | 46.66 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 189.52 Billion JPY | 99.844% |
Astellas Pharma Inc. | 1973.61 Billion JPY | 99.985% |
Chugai Pharmaceutical Co., Ltd. | 306.96 Billion JPY | 99.904% |
Ono Pharmaceutical Co., Ltd. | 115.06 Billion JPY | 99.743% |
Santen Pharmaceutical Co., Ltd. | 130.33 Billion JPY | 99.773% |
JCR Pharmaceuticals Co., Ltd. | 45.74 Billion JPY | 99.354% |
Daiichi Sankyo Company, Limited | 1763.11 Billion JPY | 99.983% |
Otsuka Holdings Co., Ltd. | 924.92 Billion JPY | 99.968% |